Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drager sales up 3.7%:

This article was originally published in Clinica

Executive Summary

Medtech revenues contributed some 65% of German company Drager's total sales of DM 1,435 million ($1,000 million) in 1995, which were up 3.7% on the previous year. When expressed in local currencies this represents growth of 8%. Medical technology sales increased around 4% in Germany and about 13% abroad. Group net profits were DM 13.7 million, down nearly 10% on 1994. The company blames high German production costs and currency effects. The company spent DM 106 million on R&D, compared with DM 93.5 million in 1994. Drager TGM, which will expand the company's equipment servicing programme for hospitals, was set up in Kirchheimbolanden, Germany, at the end of May.

You may also be interested in...



QUOTED. 13 December 2019. Todd Garner

ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs.  See what the CFO said about it here.

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Real-World Evidence Fails Another Test At US FDA

Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.

Topics

UsernamePublicRestriction

Register

MT088269

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel